National Graphite Corp.

Equities

NGRC

US6362682030

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 07:00:02 27/06/2024 pm IST			5-day change	1st Jan Change
0.05 ^USD	-.--%		-.--%	-3.85%

2015	Wolfgang Kochs to Resign from National Graphite Corp. as Director and Chief Financial Officer	CI
2015	National Graphite Corp. cancelled the transaction announced on October 17, 2012	CI

National Graphite Corp. announced that it has received $0.1 million in funding.

October 17, 2014 at 09:30 am IST

National Graphite Corp. (OTCPK:NGRC) announced a private placement of 325,000 restricted shares at $0.32 per share for gross proceeds of $104,000 on October 17, 2014. The transaction included participation from Ulrike Dickmann, Axel Kutscher, and Frank Petermeyer, three existing shareholders of Biotech Development Corp.

On October 17, 2014, National Graphite Corp. closed the transaction.

Latest news about National Graphite Corp.

Wolfgang Kochs to Resign from National Graphite Corp. as Director and Chief Financial Officer	11/15/11	CI
National Graphite Corp. cancelled the transaction announced on October 17, 2012	17/15/17	CI
National Graphite Corp. Announces Executive Changes	06/15/06	CI
National Graphite Corp. Announces Management Changes	28/14/28	CI
National Graphite Corp. entered in a share exchange agreement to acquire Biotech Development Corp. from Ulrike Dickmann, Axel Kutscher and Frank Petermeyer for $10 million.	28/14/28	CI
National Graphite Corp. completed the acquisition of Biotech Development Corp. from Ulrike Dickmann, Axel Kutscher and Frank Petermeyer.	28/14/28	CI
National Graphite Corp. announced that it has received $0.1 million in funding.	17/14/17	CI
National Graphite Corp. Cancels Chedic Graphite Drill Program	11/13/11	CI
National Graphite Corp. Signs Strategic Alliance with American Graphene LLC	03/13/03	CI
National Graphite Initiates Environmental Study on Chedic Graphite Property	23/13/23	CI
National Graphite Corp. Intends to Drill Chedic Graphite Property	05/13/05	CI
National Graphite Corp. Announces Samples from Chedic Graphite Prospect Yields 25% to 40% Grade with 1,000,000 Ton Potential	30/12/30	CI
National Graphite Corp. Appoints Howard Bouch as Director, CFO and Treasurer	09/12/09	CI
National Graphite Corp. Discovers Second High Grade Zone at its Nevada Graphite Mine	10/12/10	CI
National Graphite Corp. Announces Completion of Geophysics Survey on Nevada Graphite Property	12/12/12	CI
National Graphite Corp. completed the acquisition of 300 acres of property adjacent to the Chedic/Voltaire property in NW Nevada from GeoXplor Corp.	12/12/12	CI
National Graphite Corp. Expands Graphite Land Holdings in NW Nevada	05/12/05	CI
National Graphite Corp. agreed to acquire 300 acres of property adjacent to the Chedic/Voltaire property in NW Nevada from GeoXplor Corp.	05/12/05	CI
National Graphite Corp. will Change its Ticker to NGRC from LUCB	06/12/06	CI
Lucky Boy Silver Corp has Changed its Name to National Graphite Corp	06/12/06	CI
Lucky Boy Silver Corp acquired Chedic graphite property from GeoXplor Corp. for $1.7 million.	02/12/02	CI
National Graphite Corp. Acquires 65 Graphite Claim Block in Quebec, Canada	24/12/24	CI
Lucky Boy Silver Corp acquired 65 claims in Lochaber Township in Quebec from Habitants Minerals Ltd. for $0.1 million.	23/12/23	CI

Chart National Graphite Corp.

Duration

Period

More charts

Company Profile

National Graphite Corp., formerly Lucky Boy Silver Corporation, is a biopharmaceutical risk/cost-sharing company. The Company is pursuing the commercial development of a drug candidate, elafin, for the treatment of postoperative inflammatory complications. Elafin is a human identic protein. The Company operates in Germany, in collaboration with clinical-stage companies that develop new biological entities or new therapeutically platforms in the treatment for various diseases, rare diseases and diseases with unmet needs. Biotech Development Corp. is the Company's subsidiary. As of February 28, 2015, the Company had not generated any revenues.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NATIONAL GRAPHITE CORP.	-3.85%	77.15L
VERTEX PHARMACEUTICALS INCORPORATED	+15.82%	12TCr
REGENERON PHARMACEUTICALS, INC.	+20.35%	11TCr
ARGENX SE	+17.47%	2.6TCr
BIONTECH SE	-25.31%	1.94TCr
GENMAB A/S	-19.51%	1.59TCr
BEIGENE, LTD.	-19.67%	1.51TCr
WUXI APPTEC CO., LTD.	-46.87%	1.51TCr
SAREPTA THERAPEUTICS, INC.	+62.55%	1.49TCr
NEUROCRINE BIOSCIENCES, INC.	+6.34%	1.39TCr

Bio Therapeutic Drugs